Welcome to GSK’s product website

Here you will find information about GSK’s medicines and vaccines

I’m a UK healthcare professional

Important notice: this site is intended for UK healthcare professionals. By entering this site, you are confirming that you are a UK healthcare professional. This site may contain promotional information.

I’m a member of the UK public

This site is intended for members of the UK public, patients and their carers.

M.C. Last updated: November 2018. UK/COM/0106/15(4)

M.C. Last updated: November 2018. UK/COM/0106/15(4)

DON'T HOLD BACKStart with Anoro

as Initial Maintenance Therapy
in symptomatic COPD patients

Order a demo device

What is Anoro Ellipta?


Indication

Anoro Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD1.

Dosing

The recommended and maximum dose of Anoro Ellipta (UMEC/VI 55/22 mcg) is one inhalation once a day. If a dose is missed the next dose should be taken at the usual time the next day1.

MeetHannah*

  • AGE: 56
  • mMRC2 : 2
  • CAT SCORE : 10
  • FEV1 predicted: 65%
  • GOLD PATIENT GROUP: B
  • EXACERBATION HISTORY: None within the last 12 months
  • SYMPTOMS: Breathless on exertion, walks slower than others her age
  • HANNAH IS STILL BREATHLESS DESPITE AS-NEEDED SABA**
*Fictional patient
mMRC, modified Medical Research Council
CAT, COPD assessment test
FEV1, forced expiratory volume in one second
SABA, short-acting beta2 agonist

Which maintenance medication would you start Hannah on?

In a post hoc, pooled analysis of 3 RCTs at 24 weeks in patients not on maintenance therapy (for ≥ 30 days before screening), Anoro demonstrated:

2.4% greater improvement in lung function  vs. Tiotropium
(p<0.001)

with an extra 146mL improvement in trough FEV14,5

Initial maintenance therapy:
LAMA or LAMA/LABA?

A cross-sectional analysis of 818 COPD patients found that, despite treatment with tiotropium monotherapy, approximately 50% continue to suffer moderate to severe breathlessness (mMRC≥2)3.

Start with Anoro as an initial maintenance therapy in your symptomatic adult COPD patients.

Anoro was well tolerated and demonstrated a safety profile comparable to tiotropium HandiHaler4.

Think all
LAMA/LABAs
are the same?

In a 8 week, open-label, crossover study in patients not on maintenance therapy (for ≥ 2 weeks prior to randomisation)6:

Anoro provided a 38% reduction in rescue medication usage vs Spiolto (difference: 0.25 puffs/day)6.

Anoro was well tolerated and demonstrated a safety profile comparable to Spiolto Respimat6.

Anoro demonstrated:

1.4% superior lung function improvement vs. Spiolto
(p<0.001)

with an extra 52 mL improvement in trough FEV16

Anoro comes in the easy to use Ellipta inhaler7-9

Looking to review the guidelines in your local health economy?

Value.GSK

Value.GSK

Find out more with tailored information about Anoro and the other Ellipta devices on a portal for commissioners


Go to Value.GSK
formulary

Formulary

Information to support commissioners and healthcare professionals when making an Anoro formulary application


View evidence summary

Get started with Anoro Ellipta
for patients with COPD like Hannah

COPD assessment test (CAT) pad

Identify patients like Hannah using the CAT score pad

COPD assessment test (CAT) pad questionnaire to measure the impact of COPD on a person’s life.

Order now
Ellipta inhalation trainer

Can your patient use the Ellipta device effectively?

Ellipta inhalation training whistle that helps patients understand the correct inspiratory flow needed to use the Ellipta device.

Order now
Ellipta demonstration device

Help demonstrate the Ellipta device to patients like Hannah

Ellipta Demonstration device for healthcare professionals to show patients how to use the Ellipta device correctly.

Order now

References

  • 1. Anoro SmPC
  • 2. Stenton et al. Occupational Medicine; 2008: 58:226–227
  • 3. GSK data on file UK/UCV/0114/14
  • 4. Maleki-Yazdi M et al. Adv Ther 2016; 33:2188-2199.
  • 5. GSK DATA on file: RF/UCV/0112/15.
  • 6. Feldman G.J et al. Adv Ther 2017; 34:2518–2533
  • 7. Riley J et al. Int J Chron Obstruct Pulmon Dis 2016; 11:1873-1880.
  • 8. Svedsater H et al. BMC pulm Med 2013; 13:72-86.
  • 9. Van der Palen J et al. NPJ Primare Respir Med 2016; 26:16079.
innoviva_logo

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

© 2020 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.
Anoro Ellipta was developed in collaboration with Innoviva.

Last updated: March 2020. PM-GB-UCV-WCNT-190010 V2.0